Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Qin, L ^a   Smith, B D ^a   Tsai, H L ^a   Yaghi, N K ^a   Neela, P H ^a   Moake, M ^a   Fu, J ^a   Kasamon, Y L ^a   Prince, G T ^a   Goswami, M ^b   Rosner, G L ^a   Levitsky, H I ^a,c   Hourigan, C S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Hematology Branch   (United States)

^c Roche Glycart AG   (Switzerland)

Author keywords

Cancer vaccines; Chronic myeloid; Immunotherapy; K562 cells; Leukemia

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IMMUNOGLOBULIN G ANTIBODY; LEUKEMIA ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; TREATMENT RESPONSE;

EID: 84885336017     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.44     Document Type: Article

References (60)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832-843.
2. Hourigan CS, Levitsky HI. Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (Sudbury, Mass.) 2011; 17: 309-324.
3. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4: 127ps8.
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
5. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
8. Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011; 84: 409-421.
9. Ribas A. Tumor immunotherapy directed at PD-1. N Engl JMed 2012; 366: 2517-2519.
10. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
11. Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology 2011; 2011: 128-135.
12. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012; 118: 3123-3127.
13. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012; 120: 1390-1397.
14. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6: e23022.
15. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202-207. (Pubitemid 16183150)
16. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13(1 Pt 1): 248-251.
17. Gale RP, Horowitz MM. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1990; 6(Suppl 1): 94-97. (Pubitemid 20251421)
18. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann I Int Med 1988; 108: 806-814.
19. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
20. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-11813. (Pubitemid 26014201)
21. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002; 30: 1029-1035. (Pubitemid 35286619)
22. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003; 106: 224-231. (Pubitemid 36835175)
23. Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106: 705-714.
24. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-2175.
25. Casalegno-Garduno R, Schmitt A, Schmitt M. Clinical peptide vaccination trials for leukemia patients. Exp Rev Vaccines 2011; 10: 785-799.
26. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007; 21: 2287-2295. (Pubitemid 350011701)
27. Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998; 161: 877-889. (Pubitemid 28323553)
28. Rezvani K, Yong ASM, Mielke S, Jafarpour B, Savani BN, Le RQ et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8(+) T cells in myeloid malignancies. Haematologica 2011; 96: 432-440.
29. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination With Irradiated tumor-cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and longlasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543. (Pubitemid 23111402)
30. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocytemacrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999; 10: 1983-1991. (Pubitemid 29387912)
31. Dummer R. GVAX (Cell Genesys). Curr OpinInvest Drug 2001; 2: 844-848.
32. Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ et al. Granulocytemacrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009; 114: 1736-1745.
33. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surgery 2011; 253: 328-335.
34. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27: 5911-5918.
35. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 975-984.
36. Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 2004; 10: 799-816. (Pubitemid 39272869)
37. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006; 13: 555-562.
38. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB et al. K562/ GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010; 16: 338-347.
39. Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656-663. (Pubitemid 38140101)
40. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108. (Pubitemid 351818697)
41. Mathews ST, Plaisance EP, Kim T. Imaging systems for westerns: chemiluminescence vs infrared detection. Methods Mol Biol 2009; 536: 499-513.
42. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005; 106: 938-945. (Pubitemid 41076438)
43. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. International journal of cancer. Int J Cancer 2004; 108: 704-711. (Pubitemid 38076402)
44. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 2008; 80: 461-468. (Pubitemid 351677457)
45. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26: 2186-2196.
46. el-Shami K, Smith BD. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia 2008; 22: 1658-1664.
47. Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG et al. Graft-versusleukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clinical Cancer Res 2010; 16: 2729-2739.
48. Ossenkoppele GJ, Stam AG, Westers TM, de Gruijl TD, Janssen JJ, van de Loosdrecht AA et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003; 17: 1424-1426. (Pubitemid 36857358)
49. Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR et al. Generation of multi-leukemia antigen-specific T cells to enhance the graftversus- leukemia effect after allogeneic stem cell transplant. Leukemia 2013; 27: 1538-1547.
50. Chellaiah A, Davis A, Mohanakumar T. Cloning of a unique human homologue of the Escherichia coli DNAJ heat shock protein. Biochim Biophys Acta 1993; 1174: 111-113. (Pubitemid 23224145)
51. Terada K, Kanazawa M, Bukau B, Mori M. The human DnaJ homologue dj2 facilitates mitochondrial protein import and luciferase refolding. J Cell Biol 1997; 139: 1089-1095. (Pubitemid 27523199)
52. Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 2007; 21: 93-101. (Pubitemid 44921840)
53. Macario AJ, Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 2005; 353: 1489-1501. (Pubitemid 41400923)
54. Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 2002; 169: 1102-1109. (Pubitemid 34753471)
55. Vaughan St HA, Clair F, Scanlan MJ, Chen YT, Maraskovsky E, Sizeland A et al. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. Cancer Immun 2004; 4: 5.
56. Jongeneel V. Towards a cancer immunome database. Cancer Immun 2001; 1: 3.
57. Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol 2009; 76: 1072-1081.
58. Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998; 53: 1626-1630. (Pubitemid 28243745)
59. Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS One 2010; 5: e11806.
60. Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A et al. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B/E. Vaccine 2012; 30: 832-836.